- Home
- STRO vs GHI Comparison
STRO vs GHI Comparison
Compare STRO & GHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- GHI
- Stock Information
- Founded
- STRO 2003
- GHI 1998
- Country
- STRO United States
- GHI United States
- Employees
- STRO N/A
- GHI N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- GHI Finance: Consumer Services
- Sector
- STRO Health Care
- GHI Finance
- Exchange
- STRO Nasdaq
- GHI Nasdaq
- Market Cap
- STRO 172.8M
- GHI 251.4M
- IPO Year
- STRO 2018
- GHI N/A
- Fundamental
- Price
- STRO $1.97
- GHI $10.57
- Analyst Decision
- STRO Strong Buy
- GHI Strong Buy
- Analyst Count
- STRO 7
- GHI 4
- Target Price
- STRO $12.14
- GHI $17.50
- AVG Volume (30 Days)
- STRO 1.4M
- GHI 124.2K
- Earning Date
- STRO 11-13-2024
- GHI 02-20-2025
- Dividend Yield
- STRO N/A
- GHI 13.99%
- EPS Growth
- STRO N/A
- GHI N/A
- EPS
- STRO N/A
- GHI 0.61
- Revenue
- STRO $160,955,000.00
- GHI $34,307,528.00
- Revenue This Year
- STRO N/A
- GHI N/A
- Revenue Next Year
- STRO N/A
- GHI $10.35
- P/E Ratio
- STRO N/A
- GHI $17.25
- Revenue Growth
- STRO 230.90
- GHI 28.98
- 52 Week Low
- STRO $1.70
- GHI $10.32
- 52 Week High
- STRO $6.13
- GHI $17.24
- Technical
- Relative Strength Index (RSI)
- STRO 31.89
- GHI 36.35
- Support Level
- STRO $1.70
- GHI $10.32
- Resistance Level
- STRO $3.01
- GHI $11.05
- Average True Range (ATR)
- STRO 0.20
- GHI 0.41
- MACD
- STRO -0.01
- GHI 0.00
- Stochastic Oscillator
- STRO 20.61
- GHI 20.66
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.